ENहिन्दी soon

What should I ask my doctor about GLP-1 medicines?

Answer a few questions and get a printable visit sheet: what to bring, questions for your situation, how to check your doctor, and when to call 112.

Takes about 2 minutes Nothing you type leaves your device Every question cites its source
Step 1 of 9Who it's for
Who is this visit sheet for?

We'll write the sheet in the right voice: "my" for you, "their" for someone else.

Age (optional)
Sex (optional; sets the waist cut-off and pregnancy questions)
What's the main reason for the visit?

Pick the closest one. It changes which questions come first.

Do you have any of these health conditions?

Tick any that apply and skip the rest. Each one you tick adds a question for the doctor to your sheet.

Linked to weight or sugar
Need extra care with these medicines
Personal or family history
Which medicines do you take now?

Some of these change what the doctor needs to plan. Tick all that apply.

Could you be pregnant, or are you planning a baby?

These medicines aren't used in pregnancy, and some affect the pill. This step is skipped if you chose "Man".

Which tests have you had in the last 3 months?

Tick the ones with a report you can bring. The sheet asks about the rest.

What worries you most?

Pick as many as you like. Each adds a sourced question.

Height, weight and waist

Optional. If you add them, the sheet shows BMI and a waist note using Indian cut-offs. Skip this if you'd rather be measured at the clinic.

Height
Weight
Waist (around the navel, breathing out gently)
Anything else the doctor should know?

Optional. For example: past attempts at losing weight, side effects so far, or a surgery date. It goes into the "About" box, and you can edit it on the sheet too.

Next, you'll see the sheet. You can tick items, edit any line, add your own questions, then print or save it as a PDF.

Private by design: the sheet is built in your browser. Nothing is sent or stored unless you choose to email it to yourself, and nothing goes in the link. Privacy notice

Your visit sheet is ready

Tap any line in "About" or any question to change the words. Remove questions with ×, or add your own. Ticks print too.

What this means

What this doesn't mean

  • It isn't a yes or a no. No tool can tell whether a GLP-1 medicine suits someone. A doctor decides that after a history, an examination and tests.
  • It isn't every question. It covers the common ones and those your answers point to. Your doctor may ask about things not listed here.
  • Don't change any medicine on your own. The dose questions are for the doctor to answer, not for you to act on before the visit.

Why each question is on your sheet

The rule behind each question for your situation, with its source. The numbers match the sources at the foot of the sheet. All checked 5 Oct 2026.

    Read before the visit

    How this works

    You answer up to 9 short questions. Only the first one is needed. The tool then picks questions from a fixed list, and every question is tied to a source: a drug label, an Indian guideline or a government rule.1,2,5

    Eight core questions go on every sheet. They come from the doctor-visit checklists in Guide 4 and Guide 6. Your answers add more. For example, insulin or a sulfonylurea (glimepiride, gliclazide) adds a question about low sugar, because the Ozempic label warns about low sugar (hypos) with that mix.3

    If you add height, weight and waist, the sheet shows BMI against the Indian cut-offs: 23 to 24.9 is overweight and 25 or more is obesity.8 A waist of 90 cm (35.4 inches) or more in men, or 80 cm (31.5 inches) or more in women, signals extra belly fat.9 These numbers describe weight. They are not a threshold for medicine.

    The "Check your provider" box uses the 2020 telemedicine rules and a 1 April 2026 government statement on who may prescribe.6,7 The red box lists the symptoms from Guide 5 that need 112.

    What this can't tell you

    • Whether a GLP-1 medicine suits you, or which one. That's for a doctor who has examined you.
    • Anything about your dose. The tool never suggests one.
    • What India's own labels say. CDSCO label texts are not published online, so we use the US and European labels.2,5
    • Whether a GP's (general practitioner's) prescription is valid. The government's statement names three specialties, and CDSCO committee minutes set a similar condition for some approvals, but we found no rule covering every brand, or anything on GP prescriptions.12,13,14
    • Which batches were recalled in July 2026. The reports we found did not publish batch numbers.10

    Questions people ask

    Is anything I type saved or sent anywhere?

    No. The sheet is built inside your browser. Nothing you type is sent to us or stored, and there is no link that contains your answers. Close the tab and it's gone.

    Can I make a sheet for my mother or father?

    Yes. Choose "A family member" and the sheet is written about them. The Indian obesity guideline recommends bringing family into appointments, so family can learn about healthy food and activity and support them.1

    Which doctor should I take this sheet to?

    A government statement on 1 Apr 2026 said only endocrinologists, internal-medicine specialists and cardiologists can prescribe GLP-1 medicines.12,7 Minutes of expert committees at CDSCO, India's central drug regulator, attach a similar condition to some approvals (endocrinologist or internal-medicine specialist), but we found no rule covering every brand.13,14 Your GP can still check you and refer you.

    Why does it ask about the contraceptive pill?

    Tirzepatide (Mounjaro) can make the pill less reliable. Its label advises a non-pill method, or adding condoms, for 4 weeks after starting and after each dose increase.4 Semaglutide is not expected to affect the pill, per its European label.5

    I'm already taking a GLP-1. Is this useful for me?

    Yes. Choose "Already taking one" and the sheet becomes a review: your prescriber, your dose, the July 2026 recalls, and whether it's working well enough to continue.10,11

    Does this tell me whether I should take one?

    No. It helps you prepare. Only a doctor who has examined you and seen your tests can decide whether any medicine fits.

    Sources

    1. Madhu SV, Kapoor N, Das S, Raizada N, Kalra S. ESI clinical practice guidelines for the evaluation and management of obesity in India: an update (2025). Indian J Endocrinol Metab, 2025;29(4):355–365. DOI. Checked 5 Oct 2026.
    2. Novo Nordisk. Wegovy (semaglutide) US prescribing information, revised June 2026. PDF. Checked 5 Oct 2026.
    3. Novo Nordisk. Ozempic (semaglutide) US prescribing information, revised May 2026: sections 5, 7, 8.3. PDF. Checked 5 Oct 2026.
    4. Eli Lilly. Mounjaro (tirzepatide) US prescribing information, revised August 2026: section 7 (oral contraceptives). PDF. Checked 5 Oct 2026.
    5. European Medicines Agency. Wegovy summary of product characteristics, sections 4.2–4.6. PDF. Checked 5 Oct 2026.
    6. Board of Governors in supersession of the Medical Council of India. Telemedicine Practice Guidelines, 25 March 2020: sections 3.2.5, 3.6, 3.7 and 5. PDF. Checked 5 Oct 2026.
    7. Outlook India (PTI). Inspections, surveillance to continue against unauthorised sale and promotion of GLP-1 weight-loss drugs: Govt. 1 April 2026. Link. Checked 5 Oct 2026.
    8. Misra A et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians. J Assoc Physicians India, 2009;57:163–170. PMID 19582986. Checked 5 Oct 2026.
    9. Misra A et al. (India Obesity Commission). Revised definition of obesity in Asian Indians living in India. Diabetes Metab Syndr, 2025;19:102989. The lead author declares fees from Novo Nordisk, Eli Lilly and Indian makers (paper's own declaration). DOI. Checked 5 Oct 2026.
    10. Medical Dialogues. Recalls by Dr Reddy's, Torrent put spotlight on quality standards in India's semaglutide market. 10 July 2026. Link. Checked 5 Oct 2026.
    11. NICE (UK). Semaglutide for managing overweight and obesity, TA875, recommendation 1.2. Link. Checked 5 Oct 2026.
    12. Press Information Bureau (PIB Research). GLP-1 Drugs: Use, Risks, and Regulation ("In India, GLP-1 drugs can only be prescribed by endocrinologists, internal medicine specialists, and cardiologists"). 1 April 2026. PDF. Checked 5 Oct 2026.
    13. CDSCO. Subject Expert Committee (Endocrinology & Metabolism), recommendations of 20–21 April 2023, tirzepatide ("The drug should be sold by retail under prescription of Endocrinologist or internal medicine specialists only"). PDF · Archived copy. Checked 5 Oct 2026.
    14. CDSCO. Subject Expert Committee (Endocrinology & Metabolism), recommendations of 13–14 February 2024, semaglutide (approved warning: "To be sold by retail on the prescription of an Endocrinologist, and Internal medicine"). PDF · Archived copy. Checked 5 Oct 2026.

    The sheet itself cites up to 30 more sources, listed at its foot. Last checked 5 Oct 2026 · Next review due Jan 2027

    How this tool was made. Written by the GLP Guidebook team from the sources above and those in Guides 4, 5 and 6. It's general information, not medical advice. Talk to a qualified doctor before starting, stopping or changing any medicine. In an emergency in India, call 112. How we write